p53 Tumour suppressor gene expression in pancreatic neuroendocrine tumour cells

Gut

Volumn 38, Issue 3, 1996, Pages 403-409

  Bartz, C ^a,b   Ziske, C ^d   Wiedenmann, B ^d   Moelling, K ^b,c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Pancreatic tumour; Tumour suppressor gene

Indexed keywords

PROTEIN P53;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MUTATION; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PRIORITY JOURNAL; SUPPRESSOR GENE;

EID: 0029865728     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.3.403     Document Type: Article

References (45)

1. Morohoshi T, Held G, Klöppel G. Exocrine pancreatic tumors and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology 1983; 7: 645-61.
2. Klöppel G, Fitzgerald PJ. In: Go V, Gardener J, Brooks F, Lebenthal E, DiMagno F, Scheele G, eds. Exocrine pancreas: biology, pathobiology and diseases. New York: Raven, 1986: 649-74.
3. Lemoine N. In: Sluyser M, ed. Molecular biology of cancer genes. Chichester: Ellis Horwood, 1990: 82-118.
4. Hoorens A, Lemoine N, McLellan E, Morohoshi T, Kamisawa T, Heitz PU, et al. Pancreatic tumors with acinar cell differentiation: an analysis of cell lineage markers, p53 expression and Ki-ras-expression. Am J Pathol 1994; 143: 685-9.
5. Heitz PU, Klöppel G. Endokrine Tumoren des Pankreas und des Duodenums. Verh Dtsch Ges Pathol 1987; 71: 202-21.
6. Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M, et al. Genetic alterations during colorectaltumor development. N Engl J Med 1988; 319: 525-32.
7. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991; 253: 49-53.
8. Milner J, Metcalf E. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991; 65: 765-74.
9. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and transactivation. Cell 1991; 67: 547-56.
10. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991; 6: 873-5.
11. Fakharzahdeh S, Trusko R, George D. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991; 10: 1565-9.
12. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
13. Shaw P, Bovey R, Tary S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89: 495-8.
14. Barton CM, Staddon SL, Hughes C, Hall P, O'Sullivan C, Klöppel G, et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-82.
15. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn S, Klein-Szanto A. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor suppressor genes. Oncogene 1992; 7: 1503-11.
16. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, et al. p53 and Ki-ras alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289-98.
17. Evers BM, Townsend CM, Upp J, Allen E, Hurlbut S, Kim S, et al. Establishment and characterization of human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991; 101: 303-11.
18. Kaku M, Nishiyama T, Yagawa K, Abe M. Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma. Gann 1980; 71: 596-601.
19. Jessop NW, Hay RJ. Characteristics of two rat pancreatic exocrine cell lines derived from transplantable tumors. In Vitro Cell Dev Biol 1980; 16: 212.
20. Philippe J, Chick WL, Habener J. Multipotential phenotypic expression of genes encoding peptide hormones in rat insulinoma cell lines. J Clin Invest 1987; 79: 351-8.
21. Takaki R, Ono J, Nakamura M, Yokogawa Y, Kumae S, Hiraoka T, et al. Isolation of glucagon-secreting cell lines by cloning insulinoma cells. In Vitro Cell Dev Biol 1986; 22: 120-6.
22. Fogh J, Wright WC, Loveless J. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 1977; 58: 209-15.
23. Knudson W, Biswas C, Toole B. Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci USA 1984; 81: 6767-71.
24. Lieber M, Mazetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor cell line (Panc 1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975; 15: 741-7.
25. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979; 282: 615-6.
26. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically denned medium. Cancer Res 1992; 42: 3858-63.
27. Macnab GM, Alexander JJ, Lecatsas G, Bey E, Urbanowicz J. Hepatitis B surface antigen produced by a human hepatoma cell line. Br J Cancer 1976; 34: 509-15.
28. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976; 73: 2424-8.
29. Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 1986; 83: 3500-4.
30. Sambrook J, Maniatis T, Fritsch EF, eds. Molecular cloning. New York: CSH Laboratory Press, 1989.
31. Thein SL. A simplified method of direct sequencing of PCR amplified DNA with Sequenase T7 DNA polymerase. USB Editorial Comments 1989; 4: 8.
32. Tan TH, Wallis J, Levine A. Identification of the p53 domain involved in formation of the Simian virus 40 large T antigen-p53 complex. J Virol 1986; 59: 574-83.
33. Bouwmeester T, Gühmann S, El-Baradi T, Kalkbrenner F, van Wijk I, Milling K, et al. Molecular cloning, expression and in vitro functional characterization of Myb-related proteins in Xenopus. Mech Dev 1992; 37: 57-68.
34. Gurney EG, Harrison RO, Fenno J. Monoclonal antibodies against Simian virus 40 T antigens: evidence for distinct subclasses of large T antigen and for similarities among non-viral T antigens. J Virol 1980; 39: 752-63.
35. Dippold WG, Jay G, DeLeo AB, Khoury G, Old LJ. p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci USA 1981; 78: 1695-9.
36. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigene defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-5.
37. Hsu I, Metcalf R, Sun T, Welsh J, Wang N, Harris C. Mutational hotspot in the p53 gene in human hepatocel-lular carcinomas. Nature 1991; 350: 427-8.
38. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature 1991; 350: 429-31.
39. Ullrich SJ, Andersen CW, Mercer WE, Appella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992; 267: 15259-62.
40. Vojtesek B, Bartek J, Midgley CA, Lane D. An immunohistochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 1992; 151: 237-44.
41. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes D. Analysis of p53 expression in human tumors: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992; 101: 183-9.
42. Yoshimoto K, Iwahana H, Fukada A, Sano T, Saito S, Iakura M. Role of p53 mutations in endocrine tumorigenesis: mutation detection by PCR-single strand conformation polymorphism. Cancer Res 1992; 52: 5061-4.
43. Barbareschi M, Girlando S, Mauri F, Arrigoni G, Laurino L, Dalla Palma P, et al. Tumor suppressor gene products, proliferation and differentiation markers in lung neuroendocrine neoplasms. J Pathol 1992; 166: 343-50.
44. Iggo R, Gatter K, Bartek J, Lane D, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
45. Chaudhry A, Oberg K, Wilander E. A study of biological behaviour based on the expression of a proliferation antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992; 13: 27-35.